CAMP4 Therapeutics grants inducement options to new hires

CAMP4 Therapeutics Corporation granted non-qualified stock options to purchase an aggregate of 39,000 shares of its common stock to three newly hired employees. The grants were approved by the Compensation Committee of the Company’s Board of Directors on June 15, 2026, as an inducement material to the employees' entry into employment. The awards were issued in accordance with Nasdaq Listing Rule 5635(c)(4).

The Inducement Grants each have a ten-year term and an exercise price of $3.96 per share, which equals the closing price of CAMP4’s common stock on the Grant Date. The options will vest over a four-year period, with 25% of the shares vesting on the one-year anniversary of the employee’s first day of employment. The remainder will vest in 36 equal monthly installments, subject to the employee’s continued service with CAMP4 through the applicable vesting dates.

Grant Details

Feature	Details
Total Shares Granted	39,000
Exercise Price	$3.96 per share
Grant Date	June 15, 2026
Term	10 years
Vesting Schedule	4 years (25% at 1 year, remainder monthly)

Each Inducement Grant was granted pursuant to, and is subject to, the terms and conditions of the Company’s 2026 Inducement Plan and the applicable non-qualified stock option agreement. CAMP4 is a clinical-stage biopharmaceutical company developing regulatory RNA-targeting therapeutics designed to upregulate gene expression.

JP Morgan analyst Anupam Rama has upgraded Camp4 Therapeutics from Neutral to Overweight, citing a revised outlook for the biotechnology firm. The investment bank simultaneously increased its price target for the stock to $9, up from the previous target of $5.

The upgrade signals a shift in sentiment regarding the company's prospects. Camp4 Therapeutics is listed on NASDAQ under the ticker symbol CAMP. The new price target reflects a more bullish stance on the company's future performance compared to the prior Neutral rating.

Rating and Target Changes

The adjustment in rating and price target provides investors with a revised benchmark for the stock's valuation. The following table summarizes the changes made by JP Morgan: